Elanco Animal Health Incorporated — Form 8-K Summary
Business context and reporting period
Elanco filed a current report concerning the completion of Eli Lilly and Company’s exchange offer and the resulting change in control and board composition. The earliest reported event occurred on March 11, 2019; the filing was signed March 13, 2019.
Transaction and ownership change
- Lilly accepted 65,000,775 Lilly common shares in exchange for 293,290,000 Elanco common shares.
- The exchanged Elanco shares represented approximately 80.2% of Elanco’s outstanding common stock as of February 5, 2019.
- Following the exchange, Lilly no longer held any voting or economic interest in Elanco common stock.
Board and governance changes
- Carl L. McMillian, David A. Ricks, Aarti S. Shah and Joshua L. Smiley resigned from Elanco’s board effective March 11, 2019.
- John P. Bilbrey, Deborah T. Kochevar, Kirk McDonald and Denise Scots-Knight were appointed as new directors.
- Several continuing directors were reassigned among board classes, with terms expiring in 2019, 2020 and 2021.
- The filing identifies the new memberships and chairs of the Nominating and Corporate Governance, Compensation and Audit committees.
Financial metrics, liquidity and outlook
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, operating guidance or other financial performance metrics. It also does not provide a new business outlook or forecast.
Director compensation and other disclosures
The new non-employee directors will participate in the existing director compensation program, including an annual cash retainer of $70,000 and an annual equity award with a grant-date value of $180,000 under the Elanco Directors’ Deferral Plan.
The filing includes a press release as Exhibit 99.1 under Regulation FD. The exhibit is described as dated March 13, 2019, although the reported transaction and appointments were effective March 11, 2019.
Important facts for investors to verify
- Completion and final settlement details of the Lilly exchange offer, including the final shares accepted and issued.
- Elanco’s post-transaction ownership structure and any resulting changes in shareholder influence.
- The current board roster, director classifications and committee assignments.
- The terms and timing of director cash and equity compensation.
- Subsequent financial results, debt and liquidity information, and management guidance, none of which are provided in this 8-K.